AI Article Synopsis

  • - This study investigates how garlic supplementation impacts the way the drug docetaxel is processed in the body of women with metastatic breast cancer, focusing on the enzyme CYP3A4 which is known to interact with garlic.
  • - Patients were given docetaxel weekly, followed by a garlic supplement for 12 days, and the drug's pharmacokinetics (how it's absorbed and cleared) were measured over time.
  • - Results showed no significant changes in docetaxel clearance due to garlic for most patients, but there was a suggestion that those with a specific genetic makeup (CYP3A5*1A allele) could experience different effects.

Article Abstract

Purpose: The herbal supplement garlic (Allium sativum) is commonly used by cancer patients. Preclinical studies have shown that allicin, a major component of garlic, may affect cytochrome P450 3A4 (CYP3A4) activity. This study examines the influence of garlic supplementation on the pharmacokinetics of docetaxel, a CYP3A4 substrate.

Experimental Design: Women with metastatic breast cancer were treated with docetaxel (30 mg/m(2)) given weekly for 3 of 4 weeks. Three days after the initial dose of docetaxel, patients received 600 mg of garlic twice daily for 12 consecutive days. Docetaxel pharmacokinetics were assessed during the first three administrations.

Results: In 10 evaluable patients, the mean baseline clearance of docetaxel was 30.8 L/h/m(2) [95% confidence intervals (95% CI), 16.7-44.9]. Coadministration of garlic reduced mean clearance of docetaxel to 23.7 L/h/m(2) (95% CI, 15.5-31.8) and 20.0 L/h/m(2) (95% CI, 13.3-26.7) on days 8 and 15, respectively (P = 0.17). Additional pharmacokinetic variables of docetaxel, including peak concentration (P = 0.79), area under the curve (P = 0.36), volume of distribution (P = 0.84), and half-life (P = 0.36), were also not statistically significantly different. The mean area under the curve ratio between day 15 and day 1 was 3.74 in three individuals with the CYP3A5*1A/*1A genotype (all African American) compared with 1.02 in six individuals with the CYP3A5*3C/*3C genotype (all Caucasian).

Conclusions: This study indicates that garlic does not significantly affect the disposition of docetaxel. However, it cannot be excluded that garlic decreases the clearance of docetaxel in patients carrying a CYP3A5*1A allele.

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-06-0388DOI Listing

Publication Analysis

Top Keywords

clearance docetaxel
12
docetaxel
10
influence garlic
8
garlic allium
8
allium sativum
8
pharmacokinetics docetaxel
8
garlic affect
8
docetaxel patients
8
l/h/m2 95%
8
area curve
8

Similar Publications

Triple-negative breast cancer (TNBC) has been a clinical challenge due to its high recurrence and metastasis rates. Chemotherapy remains the primary treatment for TNBC after surgery ablation, but it lacks targeted specificity and causes side effects in normal tissues. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is significantly expressed in TNBC cells, and small interference RNA (siRNA) targeting ROR1 can effectively suppress ROR1 gene expression, thereby inhibiting proliferation and metastasis.

View Article and Find Full Text PDF

Docetaxel-tethered di-Carboxylic Acid Derivatised Fullerenes: A Promising Drug Delivery Approach for Breast Cancer.

AAPS PharmSciTech

October 2024

Department of Pharmacy, School of Chemical Science and Pharmacy, Central University of Rajasthan, Bandarsindri, Distt. Ajmer, Rajasthan, 305817, India.

Article Synopsis
  • Docetaxel (DTX) is commonly used for treating metastatic breast cancer, but resistance to this treatment poses significant challenges.
  • The study explored the creation of dicarboxylic acid-derivatized C fullerenes as a new way to deliver DTX, achieving successful conjugation and favorable characteristics for drug release.
  • The resulting nanoconjugates demonstrated improved effectiveness and safety in delivering DTX, showing enhanced bioavailability and compatibility for potential clinical use.
View Article and Find Full Text PDF

Myeloid cell leukemia 1 (Mcl-1) is a key regulator of the intrinsic apoptosis pathway. Overexpression of Mcl-1 is correlated with high tumor grade, poor survival, and both intrinsic and acquired resistance to cancer therapies. Herein, we disclose the structure-guided design of a small molecule Mcl-1 inhibitor, compound , that binds to Mcl-1 with subnanomolar affinity, inhibits growth in cell culture assays, and possesses low clearance in mouse and dog pharmacokinetic (PK) experiments.

View Article and Find Full Text PDF

Purpose: Docetaxel is a cytotoxic drug used for first-line treatment of various malignancies. It has a narrow therapeutic index and shows wide interpatient variability in clearance and toxicity. Tools for individual dose optimization are needed to maximize efficacy and avoid toxicity.

View Article and Find Full Text PDF

Background: The commercial docetaxel (DTX) formulation causes severe side effects due to polysorbate 80 and ethanol. Novel surfactant-free nanoparticle (NP) systems are needed to improve bioavailability and reduce side effects. However, controlling the particle size and stability of NPs and improving the batch-to-batch variation are the major challenges.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!